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Summary The aim of the present study was to determine the effect of middle and
long-term positive airway pressure (CPAP) treatment on the health-related quality of
life in patients with obstructive sleep apnea. We prospectively studied two groups of
patients with this disease; a group of 42 patients (33 men and 9 women) with a mean
age of 55.277.4 years and a body mass index of 33.576.4 kg/m2 treated with CPAP for
6-months, and another group of 42 patients (34 men and 8 women) with a mean age of
54.4710.5 years and a body mass index of 33.274.0 kg/m2 treated with CPAP for 18-
months. The health related quality of life was assessed by administering a Medical
Outcomes Study Short Form-36 (SF-36) questionnaire before and after CPAP therapy.
Patients treated with CPAP for 6 months only improved significantly in the vitality
dimension and this change was clinically relevant (standard error of the
measurement¼ 1.43 SEmeas). In contrast, those treated with CPAP for a long period
(18-month) showed statistically significant improvement at post-treatment in five SF-
36 dimensions: physical functioning (Po0:001), role physical (Po0:01), social
functioning (Po0:01), vitality (Po0:001), and general health perception (Po0:001).
In four of these dimensions the improvement was clinically relevant: role physical (1.16
SEmeas), social functioning (1.35 SEmeas), vitality (1.35 SEmeas), and general health
perception (2.05 SEmeas). Using two different global rating of change (independent
measures or anchors), the minimal change important difference for patients treated
with CPAP for 6 months ranged from 20.7 to 24.2 points on the vitality dimension; and
for patients with CPAP for 18-months it ranged from 2.5 to 7.5 points on the physical
role, 5.5–6.6 points on social functioning, 7.5–8.7 on vitality, and 13.5–15.5 on general
health perception dimension.
We conclude that health-related quality of life of obstructive sleep apnea patients
improves with long term CPAP treatment and these changes are clinically relevant in
several health dimensions.
& 2004 Elsevier Ltd. All rights reserved.
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Introduction
Obstructive sleep apnea (OSA) is a common
disorder affecting about 2% of middle-aged women
and 4% of middle-aged men1 and 6% of people
between the ages of 50 and 70 years.2 This disorder
is characterized by the partial or complete collapse
of the upper airway during sleep, which results in
oxyhemoglobin desaturation and transient noctur-
nal arousals and awakenings, causing marked
distortion of the normal sleep architecture.3 The
majority of OSA patients have symptoms related to
poor quality sleep, such as excessive daytime
sleepiness and tiredness, lack of concentration,
memory impairment, and at times psychological
disturbances.4 As a result of these symptoms and
functional impairments, OSA patients often report
having a poor quality of life in social, emotional,
and physical domains.5,6 Treatment with contin-
uous positive airway pressure (CPAP) has been
shown to decrease the frequency of apneic events
and oxygen desaturation during sleep, and to
reduce the severity of sleep disturbances and
daytime sleepiness.7,8 Several studies have demon-
strated that over a short period of time CPAP
relieves daytime sleepiness and improves the
health-related quality of life (HRQoL) of patients
with OSA syndrome.9–17 Other studies have demon-
strated that CPAP is also effective in the longer.18,19
However, we have found only one previous study,18
which studies the sample population over both the
short and long term. We therefore, conducted a
clinical effectiveness study to determine the
impact of CPAP therapy on both the short-term
and long-term HRQoL of patients with OSA in our
community.
Methods
Subjects
From September 2000 to December 2002, 50
consecutive adult patients from the hospital wait-
ing list (36 men, 14 women) showing clinical
symptoms of OSA were recruited for an 18-month
prospective study. Of these, 42 patients (33 men, 9
women) completed the study and 8 patients
dropped out (3 due to CPAP intolerance and 5
patients did not show up to the re-test).
Twelve months afterward, 46 patients (37 men, 9
women) were recruited from the same waiting list
in a parallel way for inclusion in a 6-month
prospective study. Of these 43 (35 men, 8 women)
completed the study and 3 patients dropped out
(1 due to CPAP intolerance and 2 patients did not
show up to the re-test). The statistical software
randomizing function to obtain the same sample
size in both groups suppressed data from one
patient.
A group of 112 subjects from the general
population was used as a control. After adjusting
for age and sex, 84 subjects were selected for
inclusion in the control group.
CPAP therapy was applied to patients having
apnea–hypopnea index (AHI) ofX30/h of sleep and
any of the following symptoms as reported by the
patient or a bedmate: daytime sleepiness, loud
snoring, nocturnal choking and awakenings, cease-
breathing events, or cardiovascular complica-
tions.20 Patients with AHI of o30/h were not
offered CPAP therapy, except in cases in which
patients had a pathologic degree of daytime
sleepiness or were suitable candidates for CPAP
therapy as determined by the treating physicians.
Subjects were excluded if they had a history of
prior surgical intervention for OSA, or other sleep
disorders.
The Review Board on Human Studies at our
institution approved the protocol, and each patient
gave his or her informed consent to participate in
the study.
Outcome measurements
Before treatment, subjects were applied a
complete case history and a standardized
questionnaires under the supervision of a trained
interviewer.
Subjective daytime sleepiness
Subjective daytime sleepiness was evaluated by
means of the Epworth sleepiness scale (ESS)21 at
baseline and repeated after CPAP treatment using
the cross-culturally valid Spanish version.22 This
scale consists of eight questions regarding the
tendency to fall asleep in situations of differing
stimulation. Each question is scored 0 to 3: The
total score can thus vary from 0 (no sleepiness) to
24 (extremely sleepy) with 10 being the upper limit
of normal.
Health related quality of life
Health related quality of life was evaluated with a
generic instrument, Medical Outcome SurveyF
Short Form 36 (SF-36).23,24 Scores of the eight SF-
36 subscales range from 0 (minimum well-being) to
100 (maximum well-being). The SF-36 addresses
ARTICLE IN PRESS
Quality of life in patients with obstructive sleep apnea 969
the following eight domains: physical functioning;
role physical, role emotional, mental health, social
functioning, vitality, bodily pain and general health
perception.
Polysomnography
Polysomnography were carried out in our Sleep
Unit; usually from midnight to 8 a.m. This
technique consisted of continuous monitoring using
a polygraph (Ultrasom Network, Nicolet, Madison,
WI, USA) and included electroencephalogram,
electro-oculogram, chin electromyogram, airflow,
electrocardiogram and measurement of chest wall
movement. The polysomnographic register was
analysed in periods of 30 s and during stages 1, 2,
3, 4 and REM according to the Rechtschaffen and
Kales method.25 Apnea was defined as the absence
of airflow for more than 10 s, and hypopnea as the
reduction of respiratory flow for at least 10 s
accompanied by a 4% or more decrease in the
saturation of hemoglobin. The average of AHI was
calculated in hourly samples of sleep. In this study
an AHI X10 was considered as diagnostic of OSA. If
the subject hado3 h of total sleep, the sleep study
was repeated. According to polysomnographic data
OSA patients were classified as mild (AHIX10 and
o30) moderate (AHIX30 and o50) and severe
(AHIX50 events/h).
The optimal CPAP level was determined in the
laboratory during the study. It was defined as the
lowest pressure associated with least number of
respiratory events and arousals and the highest
sleep efficiency.
Follow-up protocol
Questionnaires were used to evaluate all patients
at inclusion. A study-team member who was not
aware of the patient’s AHI status and did not
participate in any other aspects of clinical manage-
ment conducted all patient interviews. During each
follow-up, subjective daytime sleepiness and
HRQoL were assess. Aside from CPAP therapy, no
other interventions were introduced.
Referring physicians were permitted to modify
general medical therapy as required. All patients
received standardized instructions by Sleep Center
staff and by home health care provider at start of
CPAP treatment. Following commencement of CPAP
treatment, the patients were reviewed at the Sleep
Clinic at 1,6,12, and 18 months or when any
problem with the CPAP device or mask fit was
encountered. The home health care provider also
reviewed patients every 2 months.
CPAP compliance
The total time that CPAP units were switched on
was logged using the unit time clock. Home health
care provider obtained compliance measures. Each
time the patient was visited the number of hours
logged on the meter was recorded and the CPAP
was given a maintenance check. We set a reference
point between those patients which presented a
high grade of CPAP compliance (5 h/night or upper)
and those that did not.
CPAP satisfaction scale
At 6 month follow-up (middle-term group) and 18
month follow-up (long-term group) patients were
asked to rank CPAP treatment on a scale from 0
(‘‘no effect at all’’) to 10 (‘‘complete relief of
symptoms’’).
Data analysis and measurements
Continuous variables were expressed as the
mean7standard deviation, unless otherwise indi-
cated. The t-test, two tailed, for paired samples
was applied to test differences pre- and post-
treatment; non-normally distributed variables were
compared using Wilcoxon rank sum test. Pre-
treatment values were compared to data from our
community population (CP)Fcorrected for age and
sexFusing an independent t-test, or a non-para-
metric (Mann-Whitney) test in case of data non-
normally distributed. Same statistical procedure
was also used to determine differences between
the two groups at baseline. ESS and BMI were
analyzed in a similar fashion.
Change in SF-36 dimension scores were calcu-
lated by subtracting post-treatment values from
pre-treatment values. Association between each
dimension and the rest of interest variables were
explored using Spearman analysis correlation. The
w2-test was used to compare categorical and
ordinal data. Statistical significance was accepted
at Po0:05: All analyses were developed using the
Statistical Package for Social Sciences (SPSS, ver.
11.0; SPSS Inc. Chicago, IL, USA).
Effect sizes for each SF-36 dimension were
calculated for each variable by dividing the mean
change in a variable by the standard deviation of
the variable at baseline.26 As an indicator of the
magnitude of therapeutic benefit,27 0.20 indicates
a small effect size, 0.50 indicates moderate, and
0.80 or higher indicates large effect size.
The standardized response mean (SRM) was
calculated by dividing the mean change by the
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standard deviation of change scores.28 Similar to
the effect size, SRM values of 0.20, 0.50 and
0.80 suggest small, moderate, and large change,
respectively.
The standard error of measurement (SEmeas)
was determined by the formula29
SEmeas ¼ SDav sqrtð1 RÞ;
where sdav was the average standard deviation of
the scores of each subject in each dimension, and R
was the Cronbach’s a-coefficient of each SF-36
dimension using responses to the initial question-
naire, because we assessed the internal consistency
(the extent to which items within a dimension are
correlated with each other) of the items composing
each of domains of the SF-36 using that a-
coefficient. Patients were classified based on 1
SEmeas standard as ‘‘no change’’ (change score is
less than 1 SEmeas) or ‘‘improved’’ (change score
rises by at least 1 SEmeas).30
We used two anchors following the global rating
of change (GRoC) approach.31 Firstly, we used the
original SF-36 question number 2 that compares
current health with health one year earlier. We
used a slightly modified version depending on the
group: current health was compared to health 3 (or
18) months earlier in the 6-month group and 18
months earlier in the 18-month group (this extra
question, even though included in the SF-36
questionnaire, does not constitute a dimension).
Secondly, treatment satisfaction scale was used as
a second GRoC measure.
We examined the relationship between the GRoC
questions and changes in SF-36 dimension scores.
Firstly, Likert scale answers corresponding to the
original question number 2 of the SF-36 were
organized into 3 categories, such that the original
values ‘‘about the same’’, ‘‘somewhat worse’’, and
‘‘much worse’’ were recoded as ‘no change’; the
original ‘‘somewhat better’’ was recoded as ‘mini-
mal change’, and the original ‘‘much better’’ was
recoded as ‘moderate/large change’.
As a second GroC, we used the patient satisfac-
tion level with the CPAP treatment at the end-
point. Satisfaction scores from 1 to 6 were recoded
as ‘no change’, 7 and 8 as ‘minimal change’, and 9
and 10 points as ‘moderate/large change’.
Results
The 6-month group had a mean age of 55.277.4
and a BMI of 33.576.4 kg/m2. The polysomno-
graphic data showed 15 patients (35.9%) with
moderate OSA and 27 patients (64.1%) with
severe OSA. Daytime sleepiness was observed in
30 patients (71.5%). The 18-month group had a
mean age of 54.4710.5 years and a BMI of
33.274.0 kg/m2.
The polysomnographic data showed 16 patients
(38.1%) with moderate OSA and 26 patients (61.9%)
with severe OSA. Daytime sleepiness was found in
32 patients (76.1%). No significant differences were
found between groups in any of these variables.
After treatment, the 6-month group had a BMI of
33.676.3 kg/m2 and the 18-month group had a BMI
of 33.674.0 kg/m2. No significant differences ex-
isted between pre- and post-treatment.
Table 1 shows the statistical results for the
individual dimensions of the SF-36 both before
and after CPAP treatment for both groups in this
study. No significant difference was found between
groups at baseline for any of the SF-36 dimensions.
Patients treated with CPAP for 6 months only
improved significantly in the vitality dimension. In
ARTICLE IN PRESS
Table 1 SF-36 scores, mean (SD), for each dimension and paired t-test significance in both groups.
SF-36 Dimension 6-month group (n ¼ 42) 18-month group (n ¼ 42) CP
Pre-treat Post-treat Sig. Pre-treat Post-treat Sig.
Physical functioning 77.7 (19.8) 81.3 (18.5)* N.S. 77.6 (21.6) 85.3 (15.5) o 0.001 88.7 (14.8)
Role limitation
Physical problems 74.4 (40.0) 83.9 (34.4) N.S. 73.8 (39.7) 92.8 (22.9) o 0.01 88.2 (30.6)
Emotional problems 89.6 (26.0) 88.8 (30.9) N.S. 86.5 (33.7) 95.2 (21.5) N.S. 87.0 (33.2)
Social functioning 85.9 (22.0) 89.1 (23.0) N.S. 86.2 (18.6) 96.6 (9.0) o 0.01 88.2 (20.5)
Mental health 70.0 (25.1) 72.0 (22.8) N.S. 70.3 (23.6) 77.3 (21.5) N.S. 74.0 (20.8)
Energy/vitality 52.3 (27.8) 70.5 (20.8) o0.001 51.0 (27.9) 66.0 (22.4) o0.001 67.3 (26.6)
Bodily pain 64.2 (31.2) 69.6 (27.6) N.S. 68.5 (25.9) 71.6 (26.2) N.S. 72.5 (25.9)
General health
perception
59.2 (22.8) 60.9 (21.5) N.S. 50.6 (19.5) 66.7 (22.6) o0.001 66.7 (20.1)
CP column shows scores from the community population. Values showing significant differences between post-treatment and CP
scores are indicated (*).
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contrast, those treated with CPAP for a longer
period (18 months) significantly improved in five SF-
36 dimensions: physical functioning, role physical,
social function, vitality and general health percep-
tion. The 18-month group was also higher for role
emotional, mental health and bodily pain, although
these values were not statistically significant.
The post-treatment values were compared with
data from our community population (corrected for
age and gender), also shown in Table 1. After CPAP
treatment all SF-36 dimensions in the 18-month
group returned to community values, while in the
6-month group physical functioning did not attain
community levels.
Effect sizes, standard response means, and
standard error of measurement of changes in SF-
36 dimensions after CPAP treatment are shown in
Table 2.
For the 6-month group, small effect sizes were
found in role physical (0.24) and bodily pain (0.20)
and there was a moderate effect in the vitality
dimension (0.65). For the 18-month group, the
greatest effect sizes were for health perception
(0.82), social function (0.55), and vitality (0.54).
The smallest effect sizes were found in role
emotional (0.26), and mental health (0.29).
The results for standardized response mean are
similar to those obtained for effect size. In the 6-
month group, only the vitality dimension shows
moderate significance (0.70). In the 18-month
group: moderate significance was found for physical
functioning (0.65), social function (0.60), and
vitality (0.63) while a large effect was found in
the change of global health perception (0.96).
Physical functioning presents a small effect, how-
ever, standardized response mean has a moderate
significance.
The results for standard error of measurement
show that the 6-month group had change in one
dimension, vitality (1.42 SEmeas). However, in the
18-month group, improvements were observed in
physical problems (1.16), social functioning (1.35),
energy/vitality (1.35) and general health percep-
tion dimension (2.05).
The CPAP titration pressure ranged from 5 to
14 cm H2O (mean value¼ 7.871.51 cm H2O). 32
patients (76.1%) in the 6-month group and 31
(73.8%) in 18-month group were classified as good
compliers (P ¼ ns). Overall, CPAP was used for
5.2472.75 h/night. CPAP usage in the 6-month
group was 5.7070.57 and 5.4170.75 (P ¼ ns) in
the 18-month.
Patients in the 6-month group self-reported a
level of satisfaction of 7.4871.90 points after the
CPAP treatment, while the 18-month group re-
ported 8.2271.51 points of satisfaction. There was
no significant difference between groups. There
was association between compliance and satisfac-
tion level. There were no significant correlations
between AHI and the mean oxygen saturation
during sleep, and no significant correlations were
found between each domain of the SF-36 and the
degree of improvement in quality of life measures
after CPAP treatment.
There was moderate/large agreement in the
classification of patients between both GroCs, with
k ¼ 0:879; Po0:001 (for the 6-month group) and
k ¼ 0:643; Po0:001 (for the 18-month group). In
the 6-month group, 22 patients did not change in
terms of the SF-36 question, while 23 patients did
not change when the satisfaction scale was
considered. Minimal change was present in 13 and
14 patients, respectively (Tables 3 and 4). In the
18-month group, there was no change in 1 patient
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Table 2 Distribution and precision measures to assess score changes (pre- and post-test) in both groups.
SF-36 Dimension 6-month group (n ¼ 42) 18-month group (n ¼ 42)
Effecta SRMb SEmeasc Effect SRM SEmeas
Physical functioning 0.17 0.21 0.376 0.36 0.65 0.963
Role limitation
Physical problems 0.24 0.23 0.562 0.48 0.45 1.161
Emotional problems 0.03 0.03 0.072 0.26 0.25 0.657
Social functioning 0.14 0.15 0.327 0.55 0.60 1.356
Mental health 0.08 0.08 0.166 0.29 0.33 0.695
Energy/vitality 0.65 0.70 1.428 0.54 0.63 1.353
Bodily pain 0.20 0.17 0.468 0.14 0.12 0.346
General health perception 0.07 0.08 0.163 0.82 0.96 2.051
aEffect size.
bStandardized response mean.
cStandard error of Measurement.
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and minimal change in 20 patients in terms of the
SF-36 question; while there was no change in 2
patients and minimal change in 20 patients when
the satisfaction scale was considered. The ESS
improved on CPAP. Both groups presented
significant improvement after treatment (6-month
group: 14.373.8 vs. 7.374.1; Po0:001 and 18
month group: 13.474.5 vs. 6.174.1; Po0:001).
ESS difference in the 6-month group was 7 points
(Po0:001) and 7.3 in the 18-month group
(Po0:001).
ESS was significantly correlated with mental
health dimension prior to CPAP treatment
(r ¼ 0:28; P ¼ 0:01) and with mental health
dimension improvement after CPAP (r ¼ 0:22;
P ¼ 0:04) (Fig. 1).
In the 6-month group, 27 patients had comorbid-
ities (11 had hypertension, 3 cardiopathy, 3 hiatus
hernia, 2 COPD, 2 diabetes, and 6 other causes)
and, in 18-month group, 31 patients had comorbid-
ities (13 hypertension, 6 cardiopathy, 4 COPD, 3
depression and 5 other causes). All of the patients
were medically stable at the time of their initial
evaluation and at follow-up. The presence of
comorbidity was significantly associated with the
following SF-36 dimensions: physical functioning
(Po0:000), role physical (Po0:011) and general
health perception (Po0:002).
Discussion
This study confirmed that patients with OSA have
impaired health status as compared with the
general population, and that this impairment is
corrected with CPAP treatment. Patients treated
for 6 months with CPAP showed statistically
significant and clinically relevant improvement in
the vitality dimension. On the other hand, those
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Table 3 Average change differences in SF-36 dimension scaled scores using SF-36 Likert question 2 as a first
global rating of change.
SF-36 Dimension 6-month group (n ¼ 42) 18-month group (n ¼ 42)
No change 22 Minimal 13 Mod/Large 7 No change 1 Minimal 20 Mod/Large 21
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Physical functioning 1.59 5.64 1.92 19.84 21.42 16.51 5.00 F 9.50 14.94 6.19 8.50
Role limitation
Physical problems 11.36 29.603 19.23 34.08 57.14 47.24 5.00 F 2.50 37.08 35.71 41.51
Emotional problems 6.06 22.14 5.12 18.49 4.76 12.59 0.00 F 5.00 22.36 22.22 41.27
Social functioning 1.51 23.33 2.56 11.25 19.04 21.95 0.00 F 5.55 14.64 15.34 18.41
Mental health 4.72 28.78 2.76 13.00 21.14 21.25 0.00 F 1.60 15.59 12.00 24.78
Energy/vitality 9.77 24.56 20.76 22.71 40.00 24.49 8.00 F 8.75 17.53 20.71 28.20
Bodily pain 8.589 22.72 16.66 32.99 30.15 33.77 20.00 F 5.00 25.35 9.52 26.36
General health
perception
7.223 20.44 9.69 13.46 15.00 20.41 44.44 F 13.50 15.92 17.80 17.37
Table 4 Average change differences in SF-36 dimension scaled scores using the satisfaction level of NCPAP
treatment reported by patient as a second global rating of change.
SF-36 Dimension 6-month group (n ¼ 42) 18-month group (n ¼ 42)
No change 23 Minimal 14 Mod/Large 5 No change 2 Minimal 20 Mod/Large 20
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Physical functioning 1.30 5.68 4.28 21.64 22.00 14.40 15.00 21.21 6.25 13.84 8.50 9.04
Role limitation
Physical problems 10.86 29.02 25.00 39.22 60.00 45.41 50.00 0.82 7.50 28.21 37.50 41.75
Emotional problems 5.79 21.67 4.76 17.81 6.66 14.90 0.00 0.46 -5.00 22.36 23.33 42.02
Social functioning 1.44 22.79 6.34 17.81 15.55 16.85 11.11 0.96 6.66 13.19 16.11 18.54
Mental health 4.52 28.13 2.85 13.62 28.80 17.97 4.00 0.49 6.00 14.59 9.00 25.98
Energy/vitality 10.00 24.02 24.28 24.71 39.00 25.34 22.50 0.96 7.50 18.81 21.75 26.91
Bodily pain 8.21 22.27 14.52 33.14 44.44 26.05 5.55 0.24 4.44 26.83 12.22 26.46
General health
percep.
6.04 20.76 8.28 12.66 19.00 23.55 15.00 1.45 15.50 15.91 16.70 18.38
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treated for 18 months showed statistically
significant and clinically relevant improvement in
four out of the eight SF-36 dimensions (physical
function, role physical, vitality and general health
perception).
The effectiveness of CPAP therapy has been
widely demonstrated in previous studies, which
have generally involved short time frames.9,10,13–16
In our study, significant improvement was observed
in the patients’ vitality after 6 months of treatment
with CPAP. Although some disagreement exists in
the literature,14 our findings are corroborated by
numerous previous papers.9,10,12,15 The improve-
ment in the vitality dimension, with an effect size
value of 0.65 and standard error of the measure-
ment of 1.43 was clinically relevant.
The question of whether the improvement
resulting from short-term CPAP treatment changes
over the long term has been the focus of frequent
study. Sin et al.19 demonstrated that improved
general health perception and vitality SF-36 dimen-
sions at 3-months remain constant after 1 year on
CPAP treatment. After 18 months on CPAP, OSA
patients in our study improved their quality of life
in three more SF-36 dimensions than patients in the
6-month group. This improvement was clinically
relevant: role physical (1.16 SEmeas), social func-
tioning (1.35 SEmeas), and general health percep-
tion (2.05 SEmeas).
Daytime sleepiness is a primary symptom of OSA
and has a significant effect on health related
quality of life.32,33 However, when the SF-36 is
specifically used as a measure of health related
quality of life to analyze the relation with daytime
sleepiness, only a relatively weak correlation is
found in some domains.11–13 In our study, prior to
CPAP treatment only a negative significant correla-
tion with mental health was found. That is to say,
patients with greater daytime somnolence showed
worse mental health. However, there is also a
significant, though slight, positive correlation be-
tween mental health dimension improvement after
CPAP and ESS. In other words, a more positive
change (greater improvement in mental health) is
associated with higher somnolence values.
Other comorbidities exist in OSA patients that
can adversely affect the quality of life.11 However,
the rapid improvement observed in our study (and
other studies) after CPAP therapy suggests that the
main cause of functional impairment was, in fact,
OSA. Although some authors have found a correla-
tion between the severity of sleep and the health
profile indices,34,35 we did not find a correlation.
Our finding is consistent with previous stu-
dies11,12,36,37 a several explanation have been
advanced. Patients may have had more severe
OSA and a worsened perception of quality of life
impairment or depression.11,36 Another possibility
is that patients may have complied less with CPAP
and reported less significant change in their
functions. Our case, however, presented high CPAP
compliance levels. Finally, an influence may exist
from confounding factors such as obesity and
coexistent disease.
HRQoL are increasingly being used as primary
outcome measures. However, it is difficult to
determine the magnitude of changes in a clinical
context.38 Because no single approach to interpret
HRQoL change is perfect,28 the use of multiple
strategies is likely to enhance interpretability. By
using both distribution and anchor-based ap-
proaches, we can better determine relevant
clinically change. We, therefore, conducted a
clinical study to determine the impact of CPAP
therapy on both the short-term and long-term
HRQoL of patients with OSA in our community.
In our study, and considering those dimensions
where the SEmeas values were significant, for the
6-month group the minimal change important
difference (MCID) sets in 20.7 points using the first
GRoC, and 24.2 using the second one, for vitality.
The MCIDs for patients in the 18-month group sets
in 2.5 and 7.5 points on the physical problems
dimension, 5.5 and 6.6 points on social functioning,
7.5 and 8.7 on vitality, and 13.5 and 15.5 on general
health perception dimension. In the case of the 18-
month group, our findings are in agreement with
results found by other authors. Angst et al. found
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Figure 1 Scatter plot showing relationship between
improvement in the mental health dimension of the SF-36
with CPAP treatment and the Epworth sleepiness scale.
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the MCID ranged from 3.3 to 5.3 points on the
physical functioning.39 Hays and Morales 40 con-
cluded that MCID for the SF-36 is in the range of 3–5
point, and Ware et al. describe similar results.41
In conclusion, several important observations
result from the present study. Firstly, our findings
suggest that most OSA patients have poor HRQL. It
was observed that long-term CPAP therapy results
in a normalization of all SF-36 dimension scores,
which nearly attains general community levels.
Furthermore, these improvements were clinically
relevant in several health dimensions.
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